Expression of Cytochrome P450 3A4 and Its Clinical Significance in Human Prostate Cancer

Urology

Volumn 74, Issue 2, 2009, Pages 391-397

  Fujimura, Tetsuya ^a   Takahashi, Satoru ^b   Urano, Tomohiko ^a   Kumagai, Jinpei ^a   Murata, Taro ^a   Takayama, Kenichi ^a   Ogushi, Tetsuo ^a   Horie Inoue, Kuniko ^c   Ouchi, Yasuyoshi ^a   Kitamura, Tadaichi ^a   Muramatsu, Masami ^c   Homma, Yukio ^a   Inoue, Satoshi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4;

ADULT; AGED; ARTICLE; CANCER SURGERY; DISEASE ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; CYTOCHROME P-450 CYP3A; CYTOPLASM; EPITHELIUM; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 67651083423     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.033     Document Type: Article

References (24)

1. Culig Z., Steiner H., Bartsch G., et al. Mechanism of endocrine therapy-responsive and -unresponsive prostate tumors. Endocr Relat Cancer 12 (2005) 229-244
2. Mizokami A., Koh E., Fujita H., et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutates androgen receptor. Cancer Res 64 (2004) 765-771
3. Hara T., Nakamura K., Araki H., et al. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res 63 (2003) 5622-5628
4. Conney A.H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycystic aromatic hydrocarbons: G. H. A. Clowes memorial lecture. Cancer Res 42 (1982) 4875-4917
5. Waxman D.J., Attisano C., Guengerich P., et al. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 β-hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 263 (1988) 424-436
6. Waxman D.J., Lapenson D.P., Aoyama T., et al. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290 (1991) 160-166
7. 3 steroid metabolite in the rat ventral prostate: 5α-androstane-3β, 6α, 17β-triol. Steroids 33 (1979) 639-657
8. Isaacs J.T., McDermott I.R., and Coffey D.S. Characterization of two new enzymatic activities of the rat ventral prostate: 5α-androstane-3β, 6α, 17β-diol 6α-hydroxylase and 5α-androstane-3β, 6α, 17β-diol 7α -hydroxylase. Steroids 33 (1979) 675-692
9. Sundin M., Warner M., Haaparanta T., et al. Isolation and catalytic activity of cytochrome P450 from ventral prostate of control rats. J Biol Chem 262 (1987) 12293-12297
10. Parkinson A., Mudra D.R., Johnson C., et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199 (2004) 193-209
11. Kittles R.A., Chen W., Panguluri R.K., et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?. Hum Genet 110 (2002) 553-560
12. Plummer S.J., Conti D.V., Paris P.L., et al. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomark Prev 12 (2003) 928-932
13. Finnstrom N., Bjelfman C., Sonderstorm T.G., et al. Detection of cytochrome P450 mRNA transcripts in human prostate samples by RT-PCR. Eur J Clin Invest 31 (2001) 880-886
14. Leskela S., Honrado E., Montero-Conde C., et al. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer 14 (2007) 645-654
15. Fujimura T., Takahashi S., Urano T., et al. Differential expression of estrogen receptor β (ERβ) and its C-terminal truncated splice variant ERβcx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 289 (2001) 692-699
16. Allred D.C., Clark G.M., Elledge R., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85 (1993) 200-206
17. Kumagai J., Fujimura T., Takahashi S., et al. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate 67 (2007) 1029-1037
18. Gonzalez F.J., and Lee Y.H. Constitutive expression of hepatic cytochrome P450 genes. FASEB J 10 (1996) 1112-1117
19. Tokizane T., Shiina H., Igawa M., et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 11 (2005) 5793-5801
20. Tayeb M.T., Clark C., Haites N.E., et al. CYP3A4 and VDR gene polymorphism and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 88 (2003) 928-932
21. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995) 1393-1398
22. Rebbeck T.R., Jaffe J.M., Walker A.H., et al. Modification of clinical presentation of prostate tumors by a novel genetic variant CYP3A4. J Natl Cancer Inst 90 (1998) 1225-1229
23. Yu Y.P., Landsittel D., Jing L., et al. Gene expression alterations in prostate cancer predicting tumor aggression and predicting development of malignancy. J Clin Oncol 22 (2004) 2790-2799
24. Pascussi J.M., Gerbal-Chalon S., Drocourt L., et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619 (2003) 243-253